SMXT, ANVS and IFBD among pre-market losers

seekingalpha

28 Feb 2024

Losers: Oragenics (OGEN) -45% after pricing $2.1M stock offering.
Palatin Technologies (PTN) -37% announces results of PL9643 MELODY-1 pivotal phase 3 clinical trial in patients with dry eye disease.
Integral Ad Science Holding Corp (IAS) -26% after Q4 earnings release.
Novavax (NVAX) -19% reports fourth Quarter and full year 2023 financial results and operational highlights.
SolarMax Technology (SMXT) -18%.
3D Systems Corp. (DDD) -17% after Q4 earnings release.
Vertex Energy (VTNR) -17% reports Q4 results.
Lemonade (LMND) -16% after Q4 earnings release.
DoubleVerify Holdings (DV) -14%.
Sarcos Technology and Robotics Corporation (STRC) -14%.
Payoneer Global (PAYO) -13% after Q4 earnings release.
Annovis Bio (ANVS) -12%.
Amesite (AMST) -12%.
Bumble (BMBL) -12% after Q4 earnings release.
Recursion Pharmaceuticals (RXRX) -11% after Q4 earnings release.
Luminar Technologies (LAZR) -10% after Q4 earnings release.
Infobird Co Ltd (IFBD) -9%.
Cellectis (CLLS) -7%.
Virgin Galactic Holdings (SPCE) -7% after Q4 earnings release.
Bit Origin Ltd (BTOG) -7%.
Fusion Fuel Green Ltd (HTOO) -6%.
reAlpha Tech Corp. (AIRE) -5%.
Opko Health (OPK) -6% after Q4 earnings release.

More on pre-market losers & stocks.

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Annovis And Alzheimer's Disease: The Best-Laid Plans
Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO
Infobird to effect 1-for-8 reverse stock split to regain compliance with Nasdaq rules
Annovis falls 16% on Phase 3 data delay for Parkinson's drug

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2414432421"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2414432421\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2414432421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-02-28 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2414432421","market":"fut","top_or_hot":-1,"title":"SMXT, ANVS and IFBD among pre-market losers","media":"seekingalpha","content":"<html><body><ul> <li> <b>Losers: </b>Oragenics (OGEN) <span>-45%</span> after pricing $2.1M stock offering.</li> <li>Palatin Technologies (PTN) <span>-37% </span>announces results of PL9643 MELODY-1 pivotal phase 3 clinical trial in patients with dry eye disease.</li> <li><a href=\"https://laohu8.com/S/IAS\">Integral Ad Science Holding</a> Corp (IAS) <span>-26%</span> after Q4 earnings release.</li> <li>Novavax (NVAX) <span>-19%</span><span> reports </span>fourth Quarter and full year 2023 financial results and operational highlights<span>.</span> </li> <li><a href=\"https://laohu8.com/S/SMXT\">SolarMax Technology</a> (SMXT) <span>-18%</span>.</li> <li>3D Systems Corp. (DDD) <span>-17%</span> after Q4 earnings release.</li> <li>Vertex Energy (VTNR) <span>-17%</span> reports Q4 results.</li> <li>Lemonade (LMND) <span>-16%</span> after Q4 earnings release.</li> <li>DoubleVerify Holdings (DV) <span>-14%</span>.</li> <li>Sarcos Technology and Robotics Corporation (STRC) <span>-14%</span>.</li> <li>Payoneer Global (PAYO) <span>-13%</span> after Q4 earnings release.</li> <li>Annovis Bio (ANVS) <span>-12%</span>.</li> <li>Amesite (AMST) <span>-12%</span>.</li> <li>Bumble (BMBL) <span>-12%</span> after Q4 earnings release.</li> <li>Recursion Pharmaceuticals (RXRX) <span>-11%</span> after Q4 earnings release.</li> <li>Luminar Technologies (LAZR) <span>-10%</span> after Q4 earnings release.</li> <li>Infobird Co Ltd (IFBD) <span>-9%</span>.</li> <li>Cellectis (CLLS) <span>-7%</span>.</li> <li>Virgin Galactic Holdings (SPCE) <span>-7%</span> after Q4 earnings release.</li> <li><a href=\"https://laohu8.com/S/BTOG\">Bit Origin</a> Ltd (BTOG) <span>-7%</span>.</li> <li>Fusion Fuel Green Ltd (HTOO) <span>-6%</span>.</li> <li><a href=\"https://laohu8.com/S/AIRE\">reAlpha Tech Corp.</a> (AIRE) <span>-5%</span>.</li> <li><a href=\"https://laohu8.com/S/OPK\">Opko Health</a> (OPK) <span>-6%</span> after Q4 earnings release.</li> </ul> <div> <h2>More on pre-market losers &amp; stocks.</h2> <ul> <li>Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects</li> <li>Annovis And Alzheimer's Disease: The Best-Laid Plans</li> <li>Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO</li> <li>Infobird to effect 1-for-8 reverse stock split to regain compliance with Nasdaq rules</li> <li>Annovis falls 16% on Phase 3 data delay for Parkinson's drug</li> </ul> </div></body></html>","source":"seekingalpha_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SMXT, ANVS and IFBD among pre-market losers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSMXT, ANVS and IFBD among pre-market losers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-28 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4072977-smxt-anvs-and-ifbd-among-pre-market-losers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Losers: Oragenics (OGEN) -45% after pricing $2.1M stock offering. Palatin Technologies (PTN) -37% announces results of PL9643 MELODY-1 pivotal phase 3 clinical trial in patients with dry eye disease. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4072977-smxt-anvs-and-ifbd-among-pre-market-losers\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DV","symbol_name":"DoubleVerify Holdings, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4072977-smxt-anvs-and-ifbd-among-pre-market-losers","article_id":"2414432421","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2414432421","pubTimestamp":1709126744,"columns":[],"sourceInfo":{"source_id":"seekingalpha_hot_news","name":"SeekingAlpha"},"weMediaInfo":null,"summary":"Losers: Oragenics (OGEN) -45% after pricing $2.1M stock offering. Palatin Technologies (PTN) -37% announces results of PL9643 MELODY-1 pivotal phase 3 clinical trial in patients with dry eye disease. ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"DV":"DoubleVerify Holdings, Inc.","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","BK4138":"石油与天然气的炼制和营销","ANVS":"Annovis Bio, Inc.","AIRE":"reAlpha Tech Corp.","IAS":"Integral Ad Science Holding","RXRX":"Recursion Pharmaceuticals, Inc.","BK4562":"SPAC上市公司","OPK":"Opko Health","IFBD":"讯鸟软件","HTOO":"Fusion Fuel Green PLC","BK4564":"太空概念","PAYO":"Payoneer Global Inc.","DDD":"3D系统","BK4204":"教育服务","AMST":"Amesite Inc.","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","BK4139":"生物科技","PTN":"Palatin Technologies Inc","LMND":"Lemonade, Inc.","BTOG":"Bit Origin","BK4566":"资本集团","LU0082616367.USD":"摩根大通美国科技A（dist）","SPCE":"维珍银河","SMXT":"SolarMax Technology","BK4196":"保健护理服务","BK4587":"ChatGPT概念","VTNR":"顶点能源","BK4009":"广告","LU1823568750.SGD":"Fidelity Global Technology A-ACC SGD","BK4535":"淡马锡持仓","BK4077":"互动媒体与服务","BK4568":"美国抗疫概念","BK4537":"激光雷达概念","NFLX":"奈飞","LAZR":"Luminar Technologies, Inc.","BK4551":"寇图资本持仓","OGEN":"Oragenics Inc.","BMBL":"Bumble Inc.","NVAX":"诺瓦瓦克斯医药","BK4096":"电气部件与设备","CLLS":"Cellectis S.A."},"translate_title":"SMXT、ANVS和IFBD是盘前输家","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIRE":1,"AMST":1,"ANVS":1,"BMBL":1,"BTOG":1,"CLLS":1,"DDD":1,"DV":1,"HTOO":1,"IAS":1,"IFBD":1,"LAZR":1,"LMND":1,"NFLX":0.61,"NVAX":1,"OGEN":1,"OPK":1,"PAYO":1,"PTN":1,"RXRX":1,"SMXT":1,"SPCE":1,"STRC":1,"VTNR":1},"content_text":"Losers: Oragenics (OGEN) -45% after pricing $2.1M stock offering. Palatin Technologies (PTN) -37% announces results of PL9643 MELODY-1 pivotal phase 3 clinical trial in patients with dry eye disease. Integral Ad Science Holding Corp (IAS) -26% after Q4 earnings release. Novavax (NVAX) -19% reports fourth Quarter and full year 2023 financial results and operational highlights.  SolarMax Technology (SMXT) -18%. 3D Systems Corp. (DDD) -17% after Q4 earnings release. Vertex Energy (VTNR) -17% reports Q4 results. Lemonade (LMND) -16% after Q4 earnings release. DoubleVerify Holdings (DV) -14%. Sarcos Technology and Robotics Corporation (STRC) -14%. Payoneer Global (PAYO) -13% after Q4 earnings release. Annovis Bio (ANVS) -12%. Amesite (AMST) -12%. Bumble (BMBL) -12% after Q4 earnings release. Recursion Pharmaceuticals (RXRX) -11% after Q4 earnings release. Luminar Technologies (LAZR) -10% after Q4 earnings release. Infobird Co Ltd (IFBD) -9%. Cellectis (CLLS) -7%. Virgin Galactic Holdings (SPCE) -7% after Q4 earnings release. Bit Origin Ltd (BTOG) -7%. Fusion Fuel Green Ltd (HTOO) -6%. reAlpha Tech Corp. (AIRE) -5%. Opko Health (OPK) -6% after Q4 earnings release.   More on pre-market losers & stocks.  Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects Annovis And Alzheimer's Disease: The Best-Laid Plans Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Infobird to effect 1-for-8 reverse stock split to regain compliance with Nasdaq rules Annovis falls 16% on Phase 3 data delay for Parkinson's drug","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}